trial fibrillation (AF) is associated with higher thromboembolic risk, possibly because of the hypercoagulable state. 1,2 Elevated levels of hemostatic markers have been shown in patients with nonrheumatic AF. [2] [3] [4] [5] [6] During AF, stagnation of blood flow in the left atrial appendage (LAA) could contribute to the hypercoagulable state and clot formation in the fibrillating atria. Hemostatic markers could be therefore used for stratification of patients at high risk vs low risk for thromboembolism as demonstrated in previous studies. [1] [2] [3] [4] [5] [6] Aortic atheroma is recognized as an important marker of stroke and peripheral embolism in patients with AF. 7-9 The SPAF-III investigators reported that complex aortic plaque emerged as a risk factor of thromboembolism in patients with nonrheumatic AF, and warfarin was effective in reducing stroke in patients with AF and complex aortic plaque. 10 Complex aortic plaques with ulcerated or mobile plaques and superimposed thrombi would activate hemostatic markers. The Framingham Offspring Study raised the possibility that the increases in hemostatic factors in patients with AF were mainly caused by the confounding effect of traditional risk factors and coexistent cardiovascular diseases rather than by AF itself. 2 We recently reported that patients with nonrheumatic AF had elevated levels of D-dimer when complicated with spontaneous echocardiographic contrast (SEC) in the descending thoracic aorta. 11
trial fibrillation (AF) is associated with higher thromboembolic risk, possibly because of the hypercoagulable state. 1, 2 Elevated levels of hemostatic markers have been shown in patients with nonrheumatic AF. [2] [3] [4] [5] [6] During AF, stagnation of blood flow in the left atrial appendage (LAA) could contribute to the hypercoagulable state and clot formation in the fibrillating atria. Hemostatic markers could be therefore used for stratification of patients at high risk vs low risk for thromboembolism as demonstrated in previous studies. [1] [2] [3] [4] [5] [6] Aortic atheroma is recognized as an important marker of stroke and peripheral embolism in patients with AF. [7] [8] [9] The SPAF-III investigators reported that complex aortic plaque emerged as a risk factor of thromboembolism in patients with nonrheumatic AF, and warfarin was effective in reducing stroke in patients with AF and complex aortic plaque. 10 Complex aortic plaques with ulcerated or mobile plaques and superimposed thrombi would activate hemostatic markers. The Framingham Offspring Study raised the possibility that the increases in hemostatic factors in patients with AF were mainly caused by the confounding effect of traditional risk factors and coexistent cardiovascular diseases rather than by AF itself. 2 We recently reported that patients with nonrheumatic AF had elevated levels of D-dimer when complicated with spontaneous echocardiographic contrast (SEC) in the descending thoracic aorta. 11 Because AF and aortic atherosclerosis might contribute synergistically to increased levels of hemostatic markers, and could be associated with increased risk of thromboembolism, we determined the relationship between plasma levels of hemostatic markers and atherosclerosis in the descending thoracic aorta assessed by transesophageal echocardiography (TEE) in patients with nonrheumatic AF and in those in sinus rhythm (SR).
Methods

Study Patients
Echocardiographic and hematologic studies were performed in 106 consecutive patients (79 men, 27 women; mean age of 67±11 years) referred to a university hospital for cardiovascular assessment for stroke risk or identification of the cardiogenic source of recent embolism. Patients who received anticoagulant therapy were not included in the present study. Of these 106 patients, AF was documented electrocardiographically in 60 patients (AF group) but not in the remaining 46 patients (SR group). The study protocol was approved by the institutional ethics committee and written informed consent was given by all patients. Underlying heart diseases included the following: ischemic heart disease (n=8), hypertrophic cardiomyopathy (n=4), dilated cardiomyopathy (n=5), sick sinus syndrome (n=3), atrial septal defect (n=5), post pericarditis (n=6), and miscellaneous diseases (n=20). No apparent underlying diseases were identified in 55 patients. Baseline clinical characteristics, including body mass index, diabetes mellitus, hyperlipidemia, smoking, previous cerebral or peripheral embolic event and the use of oral antiplatelet medication at the time of echocardiographic studies, were carefully deter-mined from medical records and routine laboratory data. Patients with mitral stenosis or prosthetic valve replacement were not included in the present study.
Echocardiography
All patients underwent transthoracic echocardiography (TTE) and TEE studies after giving informed consent as in our previous study. 11 Briefly, TTE was performed with a 3.75-MHz phased-array transducer connected to an ultrasound system (SSH-140A, Toshiba, Tokyo, Japan). The dimensions of the left atrium (LA) and left ventricular ejection fraction were determined by M-mode. 12 TEE was performed with a 5-MHz multiplane transducer. Each patient was studied in the fasted state without any premedication except for topical anesthesia of the hypopharynx with lidocaine spray. Multiple standard tomographic planes were imaged, and LAA peak flow velocity, severity of SEC in the LA (LASEC) and presence of LA thrombi were determined. LASEC was diagnosed in the presence of dynamic smoke-like echoes within the LA, and its severity was defined by the criteria of Fatkin et al. 13 Atrial cavity or appendage thrombi were considered present when there was a well-circumscribed, echodense, intracavity mass that was acoustically distinct from the underlying endocardium and the pectinate muscles (Fig 1) . Severe atheroma was defined as intimal thickness of the aorta ≥4 mm (Fig 2) . 7, 14, 15 The presence of LA thrombi, severity of SEC, and aortic atherosclerosis were determined by 2 independent observers (K.N., T.H.). A third reviewer was consulted in case of disagreement (K.O.).
Determination of Hemostatic Markers
Hemostatic markers determined were as follows: platelet factor 4 (PF4) and -thromboglobulin ( -TG) levels as indices of platelet activation, thrombin-antithrombin III complex (TAT) and prothrombin fragment 1+2 (F1+2) as a marker of thrombin activity, and D-dimer and plasmin-2-plasmin inhibitor complex (PIC) as indices of active fibrinolysis. Blood samples for determination of these hemostatic markers were obtained on the day of the TEE study using the 2-syringe technique. Preparation of blood samples and determination of hemostatic markers were performed as described previously. 11 
Statistical Analysis
Data are presented as mean value ± SD. Unpaired Student's t-test was used to compare continuous variables between 2 groups. Chi-square test or Fisher's exact probability test, if indicated, was used to compare the categorical variables. Multivariate logistic regression analysis was performed to identify independent risk factors for the hypercoagulable state (SPSS 14.0; SPSS, Chicago, IL, USA). Results of multivariate analysis are expressed as odds ratios for the comparison of risk between the 10% and 90% percentiles (with 95% confidence intervals). A p-value <0.05 was considered significant. Table 1 shows the clinical characteristics and echocardiographic variables of the AF and SR subjects stratified by the aortic atherosclerotic status. Of patients with severe atherosclerosis (atheroma thickness ≥4 mm), the mean age of AF and SR subjects was similar. Prior peripheral embolism was observed more frequently in AF patients with severe atheroma. The LA was significantly larger and LAA peak flow velocity significantly lower in AF patients with severe atheroma than in SR subjects with and without severe atheroma. In addition, LAA peak flow velocity was significantly reduced in AF patients with severe atheroma than in those without; that is, a larger LA and reduced LAA peak flow velocity would be related to AF itself but not to atherosclerosis. In contrast, the LASEC grade was significantly higher in AF patients with severe atheroma than in the other 3 study groups, indicating that LASEC could be possibly related to both AF and severe atherosclerosis. There were 17 (28%) and 8 (17%) patients with aortic SEC in the AF and SR groups, respectively (p<0.05). One patient with SR who had hypertension, hypercholesterolemia, diabetes mellitus, and smoking history had a LAA throm- bus, reduced LAA flow velocity (20 cm/s) and severe atheroma (maximum thickness 5.6 mm). Plasma levels of hemostatic markers in the AF and SR subjects stratified by aortic atherosclerotic status are shown in Table 2 . Levels of F1+2 and PIC were significantly higher in AF patients with severe atheroma than in the other 3 groups. D-dimer level was higher in AF patients with severe atheroma than in either AF or SR patients without severe atheroma, whereas -TG, PF4, and TAT levels did not differ between AF patients with and without severe atheroma. Markers for platelet activation could be related to AF itself, but not to atherosclerosis, as in the case of LAA flow velocity; how- ever, activation of coagulation and fibrinolysis could be related to the presence of both AF and severe atherosclerosis. Levels of F1+2, PIC and D-dimer in SR subjects without severe atheroma did not differ significantly from AF patients without severe atheroma or SR patients with severe atheroma. Therefore, AF and severe atherosclerosis could synergistically contribute to activation of coagulation and fibrinolysis.
Results
AF and SR Patients Stratified by Aortic Atherosclerotic Status
Multiple Logistic Analysis
The results of multiple logistic analysis of the clinical characteristics related to elevated D-dimer levels and F1+2 levels are summarized in Tables 3 and 4 , respectively. AF and advanced age (≥75 years) were independently predictive of elevated D-dimer levels. Severe atherosclerosis did not emerge as a predictor of elevated D-dimer levels, but was a predictor of elevated F1+2 levels.
Discussion
The major findings of the present study are as follows. First, platelet activation was associated with the presence of AF itself, but not with aortic atherosclerosis. Second, coexistence of AF and severe atherosclerosis could be associated with reduced LAA flow velocity and formation of LASEC, thereby possibly leading to activation of coagulation and fibrinolysis. However, only AF and advanced age emerged as risk factors for enhanced fibrinolytic activity (ie, D-dimer level). Severe atheroma was the independent predictor of enhanced coagulation activity (ie, F1+2). Third, hemostatic markers were not definitely activated in patients with SR, even if they had severe aortic atherosclerosis. These results would support the observation of SPAF-III 10 that patients with nonrheumatic AF have an increased embolic risk when complicated with both dysfunction of the LAA and severe atherosclerosis.
Aortic Atheroma as Thromboembolic Risk in AF Patients
The SPAF investigators 10 reported that patients with AF who had complex aortic plaque were at high risk of thromboembolism and had an annual incidence of 12% when treated with low-intensity warfarin plus aspirin. Adjusteddose warfarin could decrease the risk of stroke by 75% in these patients. 10 Interestingly, swirling smoke-like echo in the aorta, frequently observed in patients with severe aortic atheroma, could be associated with thromboembolic risk in AF patients. [16] [17] [18] Aortic SEC could be secondary to aortic dilatation and localized blood stasis, resulting in a hypercoagulable state in patients with AF. Our previous study indicated that nonrheumatic AF patients with aortic SEC have activated coagulation and a high prevalence of thromboembolism. 11 There have been other studies to determine the association of increased plasma levels of hemostatic markers with systemic atherosclerosis. 19, 20 Feinberg et al showed an association of elevated levels of F1+2 and clinical risk factor for stroke, and a relation between -TG and atherosclerosis in patients with nonrheumatic AF of SPAF-III study; however, TEE findings were not analyzed in their study. 19 Ehlermann et al showed an association of severe aortic atheromatosis and elevated levels of fibrinogen, PIC, and D-dimer; however the subjects were not limited to AF patients. 20 Our results are consistent with those of Ehlermann et al 20 in that the coexistence of severe atherosclerosis with AF would synergistically lead to hypercoagulable state. In contrast to the results of Feinberg et al, 19 we showed an association of severe atheroma with activation of coagulation but not with activation of platelet function. This might be explained by the smaller number of subjects in the present study, as compared with SPAF-III, 19 and also by a possible selection bias.
AF and Coexistent Risk Factors
It is well established that AF itself may cause a hypercoagulable state. 6, 21, 22 The low flow rate and low shear rate associated with AF have been thought to activate the coagulation cascade. However, the incidence of embolic events would be increased when AF patients are complicated with some specific risk factors, including advanced age, history of hypertension, diabetes mellitus, heart failure, and prior stroke. 10, [23] [24] [25] Therefore, blood flow stagnation by itself is not enough to explain the mechanism of the hypercoagulable state in patients with nonrheumatic AF with these risk factors. In the Framingham Offspring Study, the increase in levels of hemostatic factors was shown to be mainly caused by the confounding effect of traditional risk factors and coexistence of cardiovascular diseases, suggesting that coexistent risk factors, rather than AF alone, might be important for elevated levels of hemostatic markers. 2 To explain the effect of coexistent risk factors on increased levels of hemostatic markers in AF patients, it should be noted that most of the clinical risk factors could be associated with promotion of atherosclerosis and endothelial dysfunction. 26 In the setting of cardiovascular diseases, including atherosclerosis, the endothelium loses its normal regulatory functions; the endothelium controls blood fluidity and coagulation through the production of factors to regulate platelet activity, the clotting cascade, and the fibrinolytic system, as well as regulating vascular tone by balancing the production of vasodilators. 26 Actually, the present study indicated that coexistence of severe atheroma and nonrheumatic AF synergistically activated coagulation and fibrinolysis. However, activation of platelet function was not detected in patients in SR with severe atheroma.
Study Limitations
First, most of our study patients had already experienced embolic events or had other cardiac diseases. Therefore, our results could be affected by the possibly hypercoagulable state of the subjects. Second, levels of hemostatic markers were determined while approximately one-third of patients were taking antiplatelet drugs. Many previous studies have indicated that hemostatic markers are not affected by aspirin. 3, 5, 27 Third, we could not determine the mechanism by which coexistence of severe atheroma and nonrheumatic AF could promote activation of coagulation and fibrinolysis, nor the effect of cholesterol-lowering statin therapy for stroke risk reduction. The site of activation of coagulation and fibrinolysis would be in the localized region with severe atheroma of the thoracic aorta, as well as in the fibrillating atria. Further investigation is needed to determine the potential advantages of statin therapy in reducing stroke risk in AF.
Although limited for these reasons, the present results indicate that coexistent severe aortic plaque and AF would activate coagulation and fibrinolysis, and thereby serve as an indicator of increased risk of embolic events. Because the number of patients was too small to draw a definite conclusion, further prospective studies on a larger scale are warranted.
